Compare SHEN & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHEN | FTRE |
|---|---|---|
| Founded | 1902 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.4M | 829.3M |
| IPO Year | 1994 | 2023 |
| Metric | SHEN | FTRE |
|---|---|---|
| Price | $15.26 | $9.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $26.00 | $14.06 |
| AVG Volume (30 Days) | 181.7K | ★ 934.4K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $357,854,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $7.12 | N/A |
| Revenue Next Year | N/A | $3.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.08 | 1.00 |
| 52 Week Low | $9.67 | $3.97 |
| 52 Week High | $15.92 | $18.67 |
| Indicator | SHEN | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 57.98 | 50.14 |
| Support Level | $14.15 | $9.56 |
| Resistance Level | $15.79 | $10.47 |
| Average True Range (ATR) | 0.43 | 0.63 |
| MACD | -0.03 | 0.15 |
| Stochastic Oscillator | 65.38 | 67.39 |
Shenandoah Telecommunications Co with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.